Cargando…
Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model
Pancreatic carcinoma ranks among the most lethal of human cancers. Besides late detection, other factors contribute to its lethality, including a high degree of chemoresistance, invasion, and distant metastases. Currently, the mainstay of therapy involves resection of local disease in a minority of...
Autores principales: | Díaz, Begoña, Ostapoff, Katherine T., Toombs, Jason E., Lo, Jason, Bonner, Michael Y., Curatolo, Adam, Adsay, Volkan, Brekken, Rolf A., Arbiser, Jack L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239497/ https://www.ncbi.nlm.nih.gov/pubmed/27438140 http://dx.doi.org/10.18632/oncotarget.10514 |
Ejemplares similares
-
Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019) -
Tris DBA ameliorates IgA nephropathy by blunting the activating signal of NLRP3 inflammasome through SIRT1‐ and SIRT3‐mediated autophagy induction
por: Wu, Chung‐Yao, et al.
Publicado: (2020) -
Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway
por: Arora, Loukik, et al.
Publicado: (2021) -
Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1
por: Desai, Tanvi J., et al.
Publicado: (2016) -
DBA Survivor
por: LaRock, Thomas
Publicado: (2010)